Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284141 | 0.88 | APLNR (0.55) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL8520807 | 0.83 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL11525177 | 0.83 | MEN1 (0.56) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL24514107 | 0.81 | APLNR (0.50) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL289320 | 0.81 | APLNR (0.46) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL18329993 | 0.79 | APLNR (0.44) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL8134537 | 0.79 | APLNR (0.44) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL5073789 | 0.79 | APLNR (0.44) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL1717954 | 0.79 | APLNR (0.48) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL9080312 | 0.79 | APLNR (0.44) | APLNRGAAMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-2074094-A1 | SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS | Pfizer Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-1999107-A2 | AMINE DERIVATIVES | Pfizer Limited (GB) | 2008-12-10 | — | — | EP | disclosed |
| US-20080090873-A1 | Sulfonamide derivatives | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2008041095-A1 | SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS | PFIZER LIMITED (GB) | 2008-04-10 | — | — | WO | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090873-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, STS | APLNR 3709/4885GAA 569/4885MEN1 3246/4885 |
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | APLNR 3329/4885GAA 1170/4885MEN1 825/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | APLNR 3329/4885GAA 1170/4885MEN1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.